The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis

British Journal of Cancer

Volumn 69, Issue 3, 1994, Pages 409-416

  Levine, A J ^a   Perry, M E ^a   Chang, A ^a   Silver, A ^a   Dittmer, D ^a   Wu, M ^a   Welsh, D ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; CYCLINE; GENE PRODUCT; MUTAGENIC AGENT; MUTANT PROTEIN; PROTEIN KINASE; PROTEIN P53; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ALLELE; AMINO ACID SEQUENCE; APOPTOSIS; CANCER; CANCER RISK; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL DIVISION; CELL GROWTH; CELL PROTECTION; CELL TRANSFORMATION; CHROMOSOME 17; CODON; DNA DAMAGE; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EXON; FAMILIAL CANCER; FIBROBLAST; GENE AMPLIFICATION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYMOCYTE; TUMOR SUPPRESSOR GENE;

ANIMAL; GENE EXPRESSION; GENES, P53; HUMAN; MICE; MUTAGENS; MUTATION; NEOPLASMS; POINT MUTATION; PROTEIN P53;

EID: 0028204538     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1994.76     Document Type: Article

References (80)

1. BARGONETTI, J., FRIEDMAN, P.N., KERN, S.E., VOGELSTEIN, B. & PRIVES, C. (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 65, 1083-1091.
2. BENCHIMOL, S., LAMB, P., CRAWFORD, L.V., SHEER, D., SHOURS, T.B., BRUNS, G.A.P. & PEACOCK, J. (1985). Transformation associated p53 protein is encoded by a gene on human chromosome 17. Som. Cell Mol. Gen., 11, 505-509.
3. BRESSAC, B., KEW, M., WANDS, J. & OZTURK, M. (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature, 350, 429-431.
4. BRUGGE, J., CURRAN, T., HARLOW, E. & MCCORMICK, F. (eds) (1991). Origins of Human Cancer. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York.
5. CALLAHAN, R. (1992). p53 mutations, another breast cancer prognostic factor. J. Natl Cancer Inst., 84, 826-827.
6. CLARKE, A.R., MAANDAG, A.R., ROON, M.V., VAN DER LUGT, N.M.T., VAN DER VALIK, M., HOOPER, M.I., BERNS, A. & RIELE, H.T. (1992). Requirement of a functional Rb-1 gene in murine development. Nature, 359, 328-330.
7. CLARKE, A.R., PURDIE, C.A., HARRISON, D.J., MORRIS, R.G., BIRD, C.C., HOOPER, M.L. & WYLLIE, A.H. (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849-852.
8. CORDON-CARDO, C., LATRES, E., DROBRYAK, M., OLIVA, M.R., POLLACK, D., WOODRUFF, J.M., BRENNAN, M. & LEVINE, A.J. (1993). Cancer Res. (in press).
9. DECAPRIO, J.A., LUDLOW, J.W., FIGGE, J., SHEW, J.Y., HUANG, C.-M., LEE, W.-H., MARSILIO, E., PAUCHA, E. & LIVINGSTON, D.M. (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell, 54, 275-283.
10. DITTMER, D., PATI, S., ZAMBETTI, G., CHU, S., TERESKY, A.K., MOORE, M., FINLAY, C. & LEVINE, A.J. (1993). p53 gain of function mutations. Nature Gen., 4, 42-46.
11. DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., MCARTHUR, M.J., MONTGOMERY, Jr, C.A., BUTEL, J.S. & BRADLEY, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
12. DYSON, N., HOWLEY, P.M., MUNGER, K. & HARLOW, E. (1989). The human papillovmavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-937.
13. EL-DEIRY, W.S., KERN, S.E., PIETENPOL, J.A., KINZLER, K.W. & VOGELSTEIN, B. (1992). Human genomic DNA sequences define a consensus binding site for p53. Nature Genet., 1, 45-49.
14. ELIYAHU, D., RAZ, A., GRUSS, P., GIVOL, D. & OREN, M. (1984). Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature, 312, 646-649.
15. FAKHARZADEH, S.S., TRUSKO, S.P. & GEORGE, D.L. (1991). Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EM BO J., 10, 1565-1569.
16. FARMER, G.E., BARGONETTI, J., ZHU, H., FRIEDMAN, P., PRYWES, R. & PRIVES, C. (1992). Wild-type p53 activates transcription in vitro. Nature, 358, 83-86.
17. FIELDS, S. & JANG, S.K. (1990). Presence of a potent transcription activating sequence in the p53 protein. Science, 249, 1046-1049.
18. FINLAY, C.A., HINDS, P.W., TAN, T.-H., ELIYAHU, D., OREN, M. & LEVINE, A.J. (1988). Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol. Cell. Biol., 8, 531-539.
19. FINLAY, C.A., HINDS, P.W. & LEVINE, A.J. (1989). The p53 protooncogene can act as a suppressor of transformation. Cell, 57, 1083-1093.
20. FORNACE, A.J., NEBERT, D.W., HOLLANDER, M.C., LUETHY, J.D., PAPATHANASIOU, M., FARGNOLI, J. & HOLBROOK, N.J. (1989). Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell. Biol., 9, 4196-4203.
21. FUNK, W.D., PAK, D.J., KARAS, R.H., WRIGHT, W.E. & SHAY, J.W. (1992). A transcriptionally active DNA binding site for human p53 protein complexes. Mol. Cell. Biol., 12, 2866-2871.
22. HARTWELL, L.H. & WEINERT, T.A. (1989). Checkpoints: controls that ensure the order of cell cycle events. Science, 246, 629-634.
23. HEIMDAL, K., LOTHE, R.A., LYSTAD, S., HOLM, R., FOSSA, S.D. & BORRESEN, A.L. (1993). No germline TP53 mutations detected in familial and bilateral testicular cancers. Genes Chrom. Cancer, 6, 92-97.
24. HERSKOWITZ, I., OGAS, J., ANDREWS, B.J. & CHANG, F. (1991). Regulators of synthesis and activity of the Gi cyclins of budding yeast. In The Cell Cycle, Cold Spring Harbor Symposium on Quant. Biology, Vol. 56, Beach, D., Stillman, B. & Watson, J.D. (eds), pp. 33-40. Cold Spring Harbor Press: Cold Spring Harbor, NY.
25. HOLLSTEIN, M., SIDRANSKY, D., VOGELSTEIN, B. & HARRIS, C.C. (1991). p53 mutations in human cancers. Science, 253, 49-53.
26. HSU, I.C., METCALF, R.A., SUN, T., WELSH, J.A., WANG, N.J. & HARRIS, C.C. (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature, 350, 427-428.
27. HUANG, H.J.S., YEE, J.K., SHEW, J.Y., CHEN, P.L., BOOKSTEIN, R., FRIEDMANN, T., LEE, E.Y.H.P. & LEE, W.-H. (1988). Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science, 242, 1563-1566.
28. JACKS, T., FAZELI, A., SCHMITT, E.M., BRONSTON, R.T., GOODELL, M.A. & WEINBERG, R.A. (1992). Effects of an Rb mutation in the mouse. Nature, 395, 295-300.
29. JONVEAUX, P. & BERGER, R. (1991). Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia, 5, 839-840.
30. KASTAN, M.B., ONYEKWERE, O., SIDRANSKY, D., VOGELSTEIN, B. & CRAIG, R.W. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
31. KASTAN, M.B., ZHAN, Q., EL-DEIRY, W.S., CARRIER, F., JACKS, T., WALSH, W.V., PLUNKETT, B.S., VOGELSTEIN, B. & FORNACE, Jr, A.J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587-597.
32. KERN, S.E., KINZLER, K.W., BAKER, S.J., NIGRO, J.M., ROTTER, V., LEVINE, A.J., FRIEDMAN, P., PRIVES, C. & VOGELSTEIN, B. (1991). Mutant p53 proteins bind DNA abnormally in vitro. Oncogene, 6, 131-136.
33. KUERBITZ, S.J., PLUNKETT, B.S., WALSH, W.V. & KASTAN, M.B. (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl Acad. Sci. USA, 89, 7491-7495.
34. LANE, D.P. & CRAWFORD, L.V. (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261-263.
35. LAVIGUEUR, A., MALTBY, V., MOCK, D., ROSSANT, J., PAWSON, T. & BERNSTEIN, A. (1989). High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol., 9, 3982-3991.
36. LEE, E.Y.-H.P., CHANG, C.-Y., HU, N., WANG, Y.-C.J., LAI, C.-C., HERRUP, K., LEE, W.-H. & BRADLEY, A. (1992). Mice deficient for RB are nonvirable and show defects in neurogenesis and hematopoiesis. Nature, 359, 288-294.
37. LEVINE, A.J. (ed.) (1992a). Cancer Surveys, Vol. 12, Tumour Suppressor Genes, the Cell Cycle and Cancer, pp. 59-79. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY.
38. LEVINE, A.J. (1992b). The p53 tumor suppressor gene (editorial). N. Engl. J. Med., 326, 1350-1352.
39. LEVINE, A.J., MOMAND, J. & FINLAY, C.A. (1991). The p53 tumor suppressor gene. Nature, 351, 453-456.
40. LEVINE, A.J., CHANG, A., DITTMER, D., NOTTERMAN, D.A., SILVER, A., THORN, K., WELSH, D. & WU, M. (1993). The p53 tumor suppressor gene. J. Lab. Clin. Med. (in press).
41. LI, F.P., FRAUMENI, J.F., MULVIHILL, J.J., BLATTNER, W.A., DREYFUS, M.G., TUCKER, M.A. & MILLER, R.M. (1988). A cancer family syndrome in twenty-four kindreds. Cancer Res., 48, 5358-5362.
42. LINZER, D.I.H. & LEVINE, A.J. (1979). Characterization of a 54K dalton cellular SV40 tumor antigen in SV40 transformed cells. Cell, 17, 43-52.
43. LIVINGSTONE, L.R., WHITE, A., SPROUSE, J., LIVANOS, E., JACKS, T. & TLSTY, T. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
44. LOWE, S.W., RULEY, H.E., JACKS, T. & HOUSEMAN, D.E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-968.
45. MALKIN, D., LI, F.P., STRONG, L.C., FRAUMENI, Jr, J.F., NELSON, C.E., KIM, D., KASSEL, J., GRYKA, M.A., BISCHOFF, F.A., TAIN-SKY, M.A. & FRIEND, S.H. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238.
46. MALTZMAN, W. & CZYZYK, L. (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694.
47. MARTINEZ, J., GEORGOFF, I., MARTINEZ, J. & LEVINE, A.J. (1991). Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev., 5, 151-159.
48. MERCER, W.E., SHIELDS, M.T., AMIN, M., SUAVE, G.J., APPELLA, E., ULLRICH, A.J. & ROMANO, J.W. (1990). Antiproliferative effects of wild-type human p53. J. Cell. Biochem., 14C, 285.
49. MICAHLOVITZ, D., HALEVY, O. & OREN, M. (1991). p53 mutations: gains or losses? J. Cell. Biochem., 45, 22-29.
50. MIETZ, J.A., UNGER, T., HUIBREGTSE, J.M. & HOWLEY, P.M. (1992). The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J., 11, 5013-5020.
51. MOMAND, J., ZAMBETTI, G.P., OLSON, D.C., GEORGE, D. & LEVINE, A.J. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell, 69, 1237-1245.
52. MONGER, K., SCHEFFNER, M., HUIBREGTSE, J.M. & HOWLEY, P. (1992). The interactions of the HPV E6 and E7 oncoproteins with tumor suppressor gene products. Cancer Surveys, 12, 197-217.
53. MURRAY, A.W. (1992). Creative blocks: cell-cycle checkpoints and feedback control. Nature, 359, 599-604.
54. MURRAY, A.W. (1993). Sunburnt fission yeast. Nature, 363, 302.
55. OBEROSLER, P., HLOCH, P., RAMSPERGER, U. & STAHL, H. (1993). P53 catalyzed annealing of complementary single-stranded nucleic acids. EMBO J., 12, 2389-2396.
56. OLINER, J.D., KINZLER, K.W., MELTZER, P.S., GEORGE, D. & VOGELSTEIN, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83.
57. PARADA, L.F., LAND, H., WEINBERG, R.A., WOLF, D. & ROTTER, D. (1984). Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature, 312, 649-651.
58. PERRY, M.E., PIETTE, J., ZAWADZKI, J.A., HARVEY, D. & LEVINE, A.J. (1993). The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl Acad. Sci. USA (in press).
59. RAYCROFT, L., WU, H. & LOZANO, G. (1990). Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science, 249, 1049-1051.
60. ROGEL, A., POPLIKER, M., WEBB, C.G. & OREN, M. (1985). p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol. Cell. Biol., 5, 2851-2855.
61. SARNOW, P., HO, Y.S., WILLIAMS, J. & LEVINE, A.J. (1982). Adenovirus ElB-58Kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54Kd cellular protein in transformed cells. Cell, 28, 387-394.
62. SCHEFFNER, M., WERNESS, B.A., HUIBREGTSE, J.M., LEVINE, A.J. & HOWLEY, P.M. (1990). The E6 oncoprotein encoded by human papillomavirus 16 or 18 promotes the degradation of p53. Cell, 63, 1129-1136.
63. SETO, E., USHEVA, A., ZAMBETTI, G.P., MOMAND, J., HORIKOSHI, N., WEINMANN, R., LEVINE, A.J. & SHENK, T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 89, 12028-12032.
64. SHAULSKY, G., GOLDFINGER, N., PELED, A. & ROTTER, V. (1991). Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Diff., 2, 661-667.
65. SHAW, P., BOVEY, R., TARDY, S., SAHLI, R., SORDAT, B. & COSTA, J. (1992). Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl Acad. Sci. USA, 89, 4495-4499.
66. SOUSSI, T., CARON DE FROMENTAL, C., MECHALI, M., MAY, P. & KRESS, M. (1987). Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene, 1, 71-78.
67. SRIVASTAVA, S., ZOU, Z., PIROLLO, K., BLATTNER, W. & CHANG, E.H. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348, 747-749.
68. STENGER, J., MAYR, G., MANN, K. & TEGTMEYER, P. (1992). Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinogen, 5, 102-106.
69. cdc2 in mammalian cells: Implication for cell cycle control and oncogenesis. Oncogene, 5, 795-801.
70. TOGUCHIDA, J., YAMAGUCHI, T., DAYTON, S.H., BEAUCHAMP, R., HERRERA, G., ISHIZAKI, K., YAMAMURI, T., MEYERS, P., LITTLE, J., SASAKI, M., WEICHSELBAUM, R. & YANDELL, D. (1992). Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N. Engl. J. Med., 326, 1301-1308.
71. WALWORTH, N., DAVEY, S. & BEACH, D. (1993). Fission yeast chkl protein kinase links the rad checkpoint pathway to cdC2. Nature, 363, 368-371.
72. WERNESS, B.A., LEVINE, A.J. & HOWLEY, P.M. (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248, 76-79.
73. WHYTE, P., RULEY, H.E. & HARLOW, E. (1988). Two regions of the adenovirus early region 1A proteins are required for transformation. J. Virol., 62, 257-265.
74. WU, X., BAYLE, J.H., OLSON, D. & LEVINE, A.J. (1993). The p53 mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
75. YEW, P.R. & BERK, A.J. (1992). Inhibition of p53 transactivation required for transformation by adenovirus E1B 55 Kd protein. Nature, 357, 82-85.
76. YIN, Y., TAINSKY, M.A., BISCHOFF, F.Z., STRONG, L.C. & WAHL, G.M. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
77. YONISH-ROUACH, E., RESNITZKY, D., LOTEM, J., SACHS, L., KIM-CHI, A. & OREN, M. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352, 345-347.
78. ZAMBETTI, G.P. & LEVINE, A.J. (1993). A comparison of the biological activities of wild-type and mutant p53. FASEB J. (in press).
79. ZAMBETTI, G.P., OLSON, D., LABOW, M. & LEVINE, A.J. (1992). A mutant p53 protein is required for the maintenance of the transformed cell phenotype in p53 plus ras transformed cells. Proc. Natl Acad. Sci. USA, 89, 3952-3956.
80. ZUR HAUSEN, H. & SCHNEIDER, A. (1987). The role of papillomaviruses in human anogenital cancer. In The Papovaviridae, Vol. 2, Papillomaviruses. Howley, P.M. & Salzman, N.P. (eds), pp. 245-263. Plenum: New York.